Results for tag: "Systemic Radiotherapy"

Systemic radiotherapy is a branch of nuclear medicine that involves the use of radiopharmaceuticals—radioactive substances used for diagnosis or therapy—that travel through the bloodstream to treat diseases such as cancer. Unlike external beam radiation therapy, which directs high-energy rays from outside the body, systemic radiotherapy delivers radiation directly to the tissue affected by the disease, minimizing damage to surrounding healthy tissues. Radiopharmaceuticals used in systemic therapy may come in different forms, such as injections or capsules, and they emit radiation to kill or damage diseased cells. Within the context of nuclear medicine, systemic radiotherapy represents a vital therapeutic modality, especially for the treatment of certain cancers like thyroid cancer, where radioiodine therapy is well-established. Advances in radiopharmacology, the study and development of radiopharmaceuticals, have led to the creation of targeted therapies that can seek out specific cellular processes or receptors, offering more advanced and personalized treatment options. Several major companies are active in the systemic radiotherapy market, contributing to its development and expansion. These firms include Bayer AG, which offers targeted radioligand therapies, and Novartis AG, known for its advances in cancer treatment with radiolabeled compounds. Other key players include GE Healthcare, providing a range of nuclear imaging and radiotherapy products, and Curium, a major manufacturer of nuclear medicine radiopharmaceuticals. Lastly, Lantheus Holdings focuses on diagnostics and targeted therapeutics for the management of various diseases. Show Less Read more